Trial Profile
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Lung-MAP Sub-Study
- 25 May 2021 Status changed from active, no longer recruiting to completed.
- 13 Dec 2017 Planned End Date changed from 1 Jun 2020 to 1 Apr 2022.
- 13 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Apr 2022.